CDH1 and prostate neoplasm: Notably, patients whose prostate tumors showed an E-cadherin-positive phenotype (defined by having ≥75% E-cadherin expression) had a significantly longer recurrence-free survival than those expressing <75% E-cadherin (Fig.1C; P = 0.025).